NASDAQ:GBT - Global Blood Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $93.82
  • Forecasted Upside: 115.69 %
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$43.50
▼ -5.69 (-11.57%)
1 month | 3 months | 12 months
Get New Global Blood Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GBT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GBT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$93.82
▲ +115.69% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Global Blood Therapeutics in the last 3 months. The average price target is $93.82, with a high forecast of $152.00 and a low forecast of $45.00. The average price target represents a 115.69% upside from the last price of $43.50.
Buy
The current consensus among 17 investment analysts is to buy stock in Global Blood Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/4/2019
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/3/2019
  • 0 strong buy ratings
  • 10 buy ratings
  • 5 hold ratings
  • 0 sell ratings
3/2/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 5 hold ratings
  • 0 sell ratings
5/31/2020
  • 0 strong buy ratings
  • 14 buy ratings
  • 7 hold ratings
  • 0 sell ratings
8/29/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 0 sell ratings
11/27/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/26/2021
  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings
2/25/2021

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 5 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/25/2021William BlairDowngradeOutperform ➝ Market PerformHigh
i
1/20/2021Piper SandlerDowngradeOverweight ➝ Neutral$75.00 ➝ $50.00Low
i
Rating by Joseph Catanzaro at Piper Sandler
12/16/2020Morgan StanleyLower Price TargetEqual Weight$67.00 ➝ $45.00Low
i
12/15/2020HC WainwrightReiterated RatingBuy$75.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/8/2020William BlairReiterated RatingBuyMedium
i
12/3/2020Royal Bank of CanadaInitiated CoverageOutperform$75.00High
i
11/18/2020Cantor FitzgeraldLower Price TargetOverweight$133.00 ➝ $120.00Low
i
Rating by A. Young at Cantor Fitzgerald
11/9/2020TruistLower Price Target$78.00 ➝ $55.00Low
i
11/6/2020Canaccord GenuityLower Price TargetHold$64.00 ➝ $45.00High
i
11/6/2020Morgan StanleyLower Price TargetEqual Weight$68.00 ➝ $67.00High
i
11/6/2020Roth CapitalLower Price TargetBuy$131.00 ➝ $128.00High
i
Rating by E. Piros at Roth Capital
11/6/2020Stifel NicolausLower Price TargetBuy$120.00 ➝ $101.00High
i
11/6/2020Piper SandlerBoost Price TargetOverweight$75.00 ➝ $120.00High
i
Rating by Joseph Catanzaro at Piper Sandler
11/6/2020OppenheimerLower Price TargetOutperform$102.00 ➝ $92.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/6/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
i
10/13/2020Morgan StanleyLower Price TargetEqual Weight$75.00 ➝ $68.00High
i
10/6/2020Evercore ISIInitiated CoverageOutperform$102.00Medium
i
8/25/2020WedbushBoost Price Target$145.00 ➝ $152.00Medium
i
Rating by Liana Moussatos at Wedbush
8/24/2020Raymond JamesInitiated CoverageOutperform$115.00Medium
i
8/6/2020HC WainwrightReiterated RatingBuy$150.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/6/2020Stifel NicolausBoost Price TargetBuy$113.00 ➝ $118.00High
i
Rating by Benjamin Burnett at Stifel Nicolaus
7/29/2020Piper SandlerReiterated RatingBuy$120.00Low
i
Rating by Joseph Catanzaro at Piper Sandler
7/20/2020Roth CapitalInitiated CoverageBuy$129.00Low
i
Rating by E. Piros at Roth Capital
7/13/2020Bank of AmericaInitiated CoverageBuy$92.00High
i
7/1/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$91.00 ➝ $103.00High
i
6/25/2020HC WainwrightReiterated RatingBuy$150.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/25/2020Canaccord GenuityReiterated RatingHoldLow
i
6/23/2020WedbushReiterated RatingBuy$145.00High
i
Rating by Liana Moussatos at Wedbush
6/15/2020OppenheimerReiterated RatingBuy$101.00High
i
6/12/2020Wells Fargo & CompanyReiterated RatingBuyHigh
i
Rating by Jim Birchenough at Wells Fargo & Company
6/10/2020Canaccord GenuityReiterated RatingHoldLow
i
5/12/2020WedbushReiterated RatingBuy$145.00Low
i
Rating by Liana Moussatos at Wedbush
5/7/2020Cantor FitzgeraldBoost Price Target$105.00 ➝ $130.00Low
i
5/7/2020NomuraReiterated RatingBuy$112.00Low
i
5/7/2020Wells Fargo & CompanyBoost Price TargetOverweight$122.00 ➝ $133.00Medium
i
5/7/2020OppenheimerBoost Price TargetOutperform$88.00 ➝ $101.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
5/7/2020Morgan StanleyBoost Price TargetEqual Weight$70.00 ➝ $75.00High
i
4/27/2020Stifel NicolausInitiated CoverageBuy$112.00Low
i
4/15/2020Morgan StanleyLower Price TargetEqual Weight$71.00 ➝ $70.00Low
i
3/19/2020WedbushReiterated RatingBuy$145.00Medium
i
Rating by Liana Moussatos at Wedbush
3/18/2020OppenheimerLower Price Target$100.00 ➝ $88.00Low
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
3/18/2020Canaccord GenuityReiterated RatingHold$60.00Medium
i
3/5/2020Canaccord GenuityReiterated RatingHold$60.00Low
i
3/3/2020Morgan StanleyLower Price TargetEqual Weight$80.00 ➝ $71.00High
i
1/31/2020SunTrust BanksDowngradeBuy ➝ Hold$110.00 ➝ $75.00High
i
1/17/2020Morgan StanleyBoost Price TargetEqual Weight$79.00 ➝ $80.00Medium
i
Rating by Matthew Harrison at Morgan Stanley
12/23/2019Piper Jaffray CompaniesReiterated RatingBuy$120.00N/A
i
Rating by Danielle Brill at Piper Jaffray Companies
12/22/2019WedbushReiterated RatingBuy$143.00Medium
i
Rating by Liana Moussatos at Wedbush
12/18/2019William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
12/17/2019JPMorgan Chase & Co.Boost Price TargetEqual Weight$58.00 ➝ $79.00Low
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
12/10/2019Piper Jaffray CompaniesBoost Price Target$95.00 ➝ $120.00High
i
12/9/2019OppenheimerReiterated RatingBuy$100.00Low
i
11/26/2019Nomura SecuritiesBoost Price TargetBuy$109.00 ➝ $112.00High
i
Rating by Christopher Marai at Nomura Securities
11/26/2019WedbushReiterated RatingBuy$143.00High
i
Rating by Liana Moussatos at Wedbush
11/26/2019Janney Montgomery ScottBoost Price TargetBuy$75.00 ➝ $90.00High
i
11/26/2019SunTrust BanksBoost Price TargetBuy$110.00High
i
11/26/2019Piper Jaffray CompaniesBoost Price TargetOverweight$80.00 ➝ $95.00High
i
11/25/2019Cantor FitzgeraldReiterated RatingBuy$110.00 ➝ $98.00High
i
Rating by A. Young at Cantor Fitzgerald
11/6/2019Canaccord GenuityInitiated CoverageHold$50.00High
i
10/17/2019Cantor FitzgeraldReiterated RatingOverweightHigh
i
Rating by A. Young at Cantor Fitzgerald
10/14/2019SunTrust BanksBoost Price TargetBuy$100.00Low
i
10/9/2019CowenSet Price TargetBuy$83.00Low
i
Rating by Ritu Baral at Cowen Inc
10/9/2019WedbushReiterated RatingBuy$120.00Low
i
Rating by Liana Moussatos at Wedbush
10/9/2019Wells Fargo & CompanyBoost Price TargetOutperform$96.00 ➝ $104.00Medium
i
10/9/2019HC WainwrightReiterated RatingBuy$150.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/8/2019William BlairReiterated RatingBuyLow
i
Rating by Raju Prasad at William Blair
9/12/2019WedbushReiterated RatingBuy$120.00Medium
i
Rating by Liana Moussatos at Wedbush
9/6/2019HC WainwrightSet Price TargetBuy$150.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
9/5/2019CowenSet Price TargetBuy$83.00Low
i
Rating by Ritu Baral at Cowen Inc
9/5/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
i
Rating by Cory Kasimov at JPMorgan Chase & Co.
9/5/2019WedbushBoost Price TargetOutperform ➝ Hold$103.00 ➝ $120.00High
i
Rating by Liana Moussatos at Wedbush
8/12/2019WedbushReiterated RatingOutperform$103.00Low
i
Rating by Liana Moussatos at Wedbush
8/11/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low
i
8/9/2019Morgan StanleySet Price TargetHold$60.00Medium
i
Rating by Matthew Harrison at Morgan Stanley
8/8/2019CowenReiterated RatingBuy$83.00Low
i
8/8/2019HC WainwrightReiterated RatingBuy$150.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/28/2019WedbushSet Price TargetBuy$103.00Medium
i
Rating by Liana Moussatos at Wedbush
6/25/2019HC WainwrightReiterated RatingBuyLow
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/17/2019WedbushReiterated RatingBuy$107.00Medium
i
Rating by Liana Moussatos at Wedbush
6/16/2019CowenReiterated RatingBuyMedium
i
6/14/2019Cantor FitzgeraldSet Price TargetBuy$96.00 ➝ $110.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
6/11/2019WedbushReiterated RatingBuy$107.00Low
i
6/3/2019WedbushReiterated RatingBuy$95.00 ➝ $107.00High
i
5/29/2019The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$75.00Low
i
5/13/2019WedbushReiterated RatingBuy$95.00High
i
Rating by Liana Moussatos at Wedbush
5/9/2019OppenheimerBoost Price TargetOutperform$82.00 ➝ $89.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
4/18/2019WedbushReiterated RatingOutperform$95.00Medium
i
Rating by Liana Moussatos at Wedbush
4/12/2019HC WainwrightSet Price TargetBuy$150.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
4/1/2019Wells Fargo & CompanyBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $96.00Low
i
3/5/2019WedbushBoost Price TargetOutperform ➝ Outperform$91.00 ➝ $95.00Low
i
Rating by Liana Moussatos at Wedbush
3/4/2019Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$55.00 ➝ $57.00Low
i
2/28/2019JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low
i
2/22/2019GuggenheimInitiated CoverageBuy$75.00Low
i
1/30/2019William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
12/19/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$54.00 ➝ $55.00High
i
12/4/2018SunTrust BanksBoost Price TargetBuy ➝ Positive$90.00Medium
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
12/4/2018HC WainwrightSet Price TargetBuy$150.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/3/2018William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
12/3/2018Cantor FitzgeraldSet Price TargetBuy$96.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
12/3/2018OppenheimerSet Price TargetBuy$82.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/28/2018HC WainwrightReiterated RatingBuy ➝ Buy$150.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/19/2018WedbushReiterated RatingBuy$73.00Low
i
Rating by Liana Moussatos at Wedbush
11/7/2018OppenheimerSet Price TargetBuy$74.00 ➝ $82.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/7/2018William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
11/5/2018HC WainwrightSet Price TargetBuy$125.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
11/1/2018OppenheimerSet Price TargetBuy$74.00Medium
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
10/23/2018Cantor FitzgeraldSet Price TargetBuy$96.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
10/19/2018HC WainwrightSet Price TargetBuy$125.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
10/18/2018William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
10/17/2018Cantor FitzgeraldReiterated RatingBuy$96.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
10/2/2018Cantor FitzgeraldSet Price TargetBuy$96.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
9/13/2018HC WainwrightSet Price TargetBuy$125.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/23/2018Cantor FitzgeraldSet Price TargetBuy$96.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
8/23/2018HC WainwrightSet Price TargetBuy$125.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/13/2018CowenReiterated RatingBuy$83.00High
i
8/8/2018HC WainwrightSet Price TargetBuy$125.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
8/8/2018Cantor FitzgeraldReiterated RatingBuy$96.00Low
i
Rating by Elemer Piros at Cantor Fitzgerald
8/6/2018WedbushReiterated RatingOutperform ➝ Outperform$73.00Low
i
Rating by L. Moussatos at Wedbush
8/6/2018Piper Jaffray CompaniesInitiated CoverageOverweight$80.00Low
i
8/5/2018SunTrust BanksSet Price TargetBuy$70.00Low
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
8/5/2018JPMorgan Chase & Co.Reiterated RatingBuy$75.00Low
i
8/2/2018Cantor FitzgeraldReiterated RatingBuy$96.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
7/27/2018HC WainwrightReiterated RatingBuy$125.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/28/2018Nomura SecuritiesBoost Price TargetBuy ➝ Buy$91.00 ➝ $109.00High
i
6/27/2018HC WainwrightBoost Price TargetBuy ➝ Buy$73.00 ➝ $125.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
6/27/2018Wells Fargo & CompanyBoost Price TargetOutperform$78.00 ➝ $85.00High
i
6/27/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$69.00 ➝ $96.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
6/18/2018WedbushReiterated RatingOutperform$70.00Low
i
Rating by L. Moussatos at Wedbush
5/24/2018HC WainwrightSet Price TargetBuy$73.00Low
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/21/2018WedbushReiterated RatingOutperform$70.00High
i
Rating by L. Moussatos at Wedbush
5/10/2018HC WainwrightSet Price TargetBuy$73.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
5/9/2018Cantor FitzgeraldSet Price TargetBuy$69.00Medium
i
Rating by Elemer Piros at Cantor Fitzgerald
5/8/2018SunTrust BanksLower Price TargetBuy ➝ Buy$80.00 ➝ $77.00High
i
Rating by Yatin Suneja at SunTrust Banks, Inc.
5/8/2018OppenheimerLower Price TargetOutperform ➝ Outperform$79.00 ➝ $74.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
4/26/2018Needham & Company LLCReiterated RatingBuy$70.00High
i
3/21/2018Morgan StanleyDowngradeOverweight ➝ Equal Weight$61.00High
i
3/14/2018WedbushReiterated RatingOutperform$73.00Low
i
3/12/2018HC WainwrightSet Price TargetBuy$73.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
3/6/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$58.00 ➝ $61.00Low
i
3/1/2018SunTrust BanksSet Price TargetPositive ➝ Buy$80.00Medium
i
2/28/2018William BlairReiterated RatingBuyHigh
i
Rating by Raju Prasad at William Blair
2/28/2018HC WainwrightSet Price TargetBuy$73.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
2/27/2018Cantor FitzgeraldSet Price TargetOverweight ➝ Overweight$61.00 ➝ $72.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
2/13/2018Janney Montgomery ScottInitiated CoverageBuy ➝ Buy$75.00Medium
i
1/23/2018William BlairInitiated CoverageOutperform ➝ Outperform$80.00High
i
Rating by R. Prasad at William Blair
1/11/2018HC WainwrightSet Price TargetBuy$73.00Medium
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/15/2017WedbushReiterated RatingOutperform$73.00Low
i
12/14/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$51.00 ➝ $70.00Low
i
12/12/2017OppenheimerSet Price TargetBuy$53.00 ➝ $79.00High
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
12/11/2017Nomura SecuritiesBoost Price TargetBuy$91.00High
i
12/11/2017HC WainwrightSet Price TargetBuy$73.00High
i
Rating by Debjit Chattopadhyay at HC Wainwright
12/11/2017Cantor FitzgeraldSet Price TargetBuy$61.00High
i
Rating by Elemer Piros at Cantor Fitzgerald
12/4/2017WedbushReiterated RatingOutperform$73.00High
i
12/1/2017HC WainwrightInitiated CoverageBuy$73.00High
i
Rating by D. Chattopadhyay at HC Wainwright
11/13/2017OppenheimerSet Price TargetBuy$53.00N/A
i
Rating by Mark Breidenbach at Oppenheimer Holdings Inc.
11/9/2017CowenReiterated RatingBuy$83.00N/A
i
11/6/2017SunTrust BanksBoost Price TargetBuy$67.00N/A
i
10/30/2017OppenheimerSet Price TargetBuy$53.00N/A
i
10/24/2017Needham & Company LLCSet Price TargetBuy$51.00N/A
i
10/23/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
10/23/2017OppenheimerSet Price TargetBuy$53.00N/A
i
10/18/2017Needham & Company LLCSet Price TargetBuy$51.00N/A
i
10/11/2017OppenheimerSet Price TargetBuy$53.00N/A
i
10/6/2017Morgan StanleyReiterated RatingOverweight$51.00 ➝ $56.00N/A
i
9/20/2017Needham & Company LLCInitiated CoverageBuy ➝ Buy$51.00High
i
9/18/2017WedbushReiterated RatingOurperform$73.00Medium
i
Rating by L. Moussatos at Wedbush
8/14/2017CowenReiterated RatingOutperform$83.00Medium
i
8/8/2017JPMorgan Chase & Co.Reiterated RatingOverweight ➝ Overweight$44.00 ➝ $46.00Medium
i
8/4/2017OppenheimerInitiated CoverageOutperform$53.00High
i
7/11/2017Morgan StanleyReiterated RatingOverweightLow
i
5/2/2017WedbushReiterated RatingOutperform$73.00High
i
Rating by L. Moussatos at Wedbush
5/1/2017Janney Montgomery ScottInitiated CoverageBuy$37.00Low
i
4/17/2017SunTrust BanksInitiated CoverageBuy ➝ Buy$56.00High
i
3/20/2017Roth CapitalSet Price TargetBuy$47.00Low
i
Rating by M. Breidenbach at Roth Capital
3/20/2017WedbushReiterated RatingOutperform ➝ Outperform$73.00Low
i
Rating by L. Moussatos at Wedbush
3/15/2017Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$61.00Low
i
3/15/2017JPMorgan Chase & Co.Reiterated RatingBuy$44.00Medium
i
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$50.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
i
2/18/2017Roth CapitalSet Price TargetBuy$47.00N/A
i
Rating by M. Breidenbach at Roth Capital
1/10/2017JPMorgan Chase & Co.Reiterated RatingBuyN/A
i
1/4/2017JPMorgan Chase & Co.Initiated CoverageOverweight$25.00N/A
i
12/6/2016WedbushSet Price TargetBuy$73.00N/A
i
12/5/2016CowenReiterated RatingBuyN/A
i
12/5/2016Roth CapitalSet Price TargetBuy$47.00N/A
i
Rating by M. Breidenbach at Roth Capital
11/28/2016Roth CapitalSet Price TargetBuy$47.00N/A
i
Rating by M. Breidenbach at Roth Capital
11/1/2016Roth CapitalInitiated CoverageBuy$47.00N/A
i
Rating by M. Breidenbach at Roth Capital
10/26/2016CowenReiterated RatingOutperform$80.00 ➝ $83.00N/A
i
10/25/2016WedbushBoost Price TargetOutperform$66.00 ➝ $73.00N/A
i
9/30/2016Wells Fargo & CompanyInitiated CoverageOutperform$75.00 ➝ $23.05N/A
i
8/22/2016WedbushReiterated RatingOutperform$66.00N/A
i
8/14/2016Morgan StanleyReiterated RatingBuy$62.00N/A
i
8/10/2016WedbushReiterated RatingOutperform$66.00N/A
i
6/10/2016Morgan StanleyReiterated RatingBuyN/A
i
6/10/2016WedbushReiterated RatingOutperform$66.00N/A
i
6/10/2016CowenReiterated RatingBuy$80.00N/A
i
5/16/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
5/9/2016CowenReiterated RatingBuy$80.00N/A
i
Rating by Ritu Baral at Cowen Inc
4/17/2016CowenReiterated RatingBuyN/A
i
Rating by Ritu Baral at Cowen Inc
3/31/2016CowenReiterated RatingOutperform$80.00N/A
i
3/2/2016WedbushLower Price TargetOutperform$94.00 ➝ $66.00N/A
i
Rating by Heather Behanna at Wedbush
(Data available from 2/25/2016 forward)
Global Blood Therapeutics logo
Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $43.50
$42.80
$46.82

50 Day Range

MA: $48.81
$45.25
$50.85

52 Week Range

Now: $43.50
$36.49
$83.69

Volume

3,894,997 shs

Average Volume

1,099,578 shs

Market Capitalization

$2.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of Global Blood Therapeutics?

The following sell-side analysts have issued reports on Global Blood Therapeutics in the last twelve months: Bank of America Co., Canaccord Genuity, Cantor Fitzgerald, Evercore ISI, HC Wainwright, Morgan Stanley, Nomura, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Roth Capital, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist, Wedbush, Wells Fargo & Company, and William Blair.
View the latest analyst ratings for GBT.

What is the current price target for Global Blood Therapeutics?

17 Wall Street analysts have set twelve-month price targets for Global Blood Therapeutics in the last year. Their average twelve-month price target is $93.82, suggesting a possible upside of 90.7%. Wedbush has the highest price target set, predicting GBT will reach $152.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $45.00 for Global Blood Therapeutics in the next year.
View the latest price targets for GBT.

What is the current consensus analyst rating for Global Blood Therapeutics?

Global Blood Therapeutics currently has 5 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GBT will outperform the market and that investors should add to their positions of Global Blood Therapeutics.
View the latest ratings for GBT.

What other companies compete with Global Blood Therapeutics?

How do I contact Global Blood Therapeutics' investor relations team?

Global Blood Therapeutics' physical mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-741-7700 and its investor relations email address is [email protected] The official website for Global Blood Therapeutics is www.gbt.com.